Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Newsletter 17/2026 April 26, 2026
- Not All Patients Benefit Equally: New Score Refines Cabazitaxel Use April 25, 2026
- B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages April 24, 2026
- DNA Smart Drugs: Precision Cancer Treatment With a Double Lock April 22, 2026
Onchilles Pharma’s (potentially) Groundbreaking Pan-Cancer Therapeutics: Targeting the ELANE Pathway
/in Immunotherapy, Preclinical Research/by MaxEarly PSA Response as a Predictor and Mediator of Treatment Efficacy in Metastatic Hormone Sensitive Prostate Cancer
/in Post-hoc, Retrospective studies/by MaxPhase 3 trial: 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxA Phase 1 trial to keep an eye on: Thorium-227 (BAY2315497) in metastatic Castration Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxHope for Aggressive Prostate Cancer: A Case Study with T-DXd
/in Case studies/by MaxPSA Kinetics Predict Survival Outcomes in High-Volume Metastatic Prostate Cancer
/in Retrospective studies/by MaxBreaking Barriers: FDA Approval of Tecelra Marks a New Era for TCR Therapy in Solid Tumors
/in Not PCa related/by MaxNot related to prostate cancer but really interesting: allogenic CAR-T is getting good results!
/in Not PCa related/by Max